Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?
Cancer Metastasis Rev
.
2022 Sep;41(3):465-469.
doi: 10.1007/s10555-022-10060-4.
Authors
Marek Z Wojtukiewicz
1
2
,
Magda Pogorzelska
3
,
Barbara Politynska
4
Affiliations
1
Department of Oncology, Medical University of Bialystok, Bialystok, Poland. marek.wojtukiewicz@umb.edu.pl.
2
Department of Clinical Oncology, Comprehensive Cancer Center, Bialystok, Poland. marek.wojtukiewicz@umb.edu.pl.
3
Department of Clinical Oncology, Comprehensive Cancer Center, Bialystok, Poland.
4
Department of Psychology and Philosophy, Medical University of Bialystok, Bialystok, Poland.
PMID:
36066779
PMCID:
PMC9470645
DOI:
10.1007/s10555-022-10060-4
No abstract available
Keywords:
Breast cancer; Future targets; Immunotherapy; TNBC; Triple negative.
Publication types
Review
MeSH terms
Humans
Immunologic Factors
Immunotherapy
Triple Negative Breast Neoplasms* / therapy
Substances
Immunologic Factors